BioPharmSignal logoBioPharmSignal

Biotech News

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Syndax Pharmaceuticals (SNDX)Syndax PharmaceuticalsConference / presentation

– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring unique aspects of revumenib’s PK profile, including the ability to administer it with gastric acid

Related news

SNDXSyndax Pharmaceuticals2026-11-04 14:00 EST

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

SNDXSyndax Pharmaceuticals2026-10-30 13:01 EST

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

GERNGeron2026-11-03 13:00 EST

Geron Corporation to Participate in the Stifel 2026 Healthcare Conference

URGNUroGen Pharma2026-11-03 13:00 EST

UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

COGTCogent Biosciences2026-10-27 20:01 EST

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

View all latest news

Syndax Pharmaceuticals

Commercial Oncology Portfolio Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo. Revuforj Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible...

Recent company news

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

SNDXSyndax Pharmaceuticals2026-11-04 14:00 EST

Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-10-30 13:01 EST

Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases

Stock data

Close
9.37 USD
Market cap
1.63B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States